Video
21 Oct 2024

From Late Pre-clinical to Commercial – Balancing Time and Cost Sensitivities

Navigating the transition from late pre-clinical stages to commercial success in the biotech and pharmaceutical industries requires a delicate balance between speed and cost efficiency. This session will explore strategic approaches to streamline this critical phase, ensuring timely market entry while controlling cost. It will deep diver into the best practices for managing late-stage development, overcoming regulatory hurdles, and scaling up production. The speaker will share insights on optimizing resource allocation, leveraging innovative technologies, and fostering strategic partnerships to enhance both speed and cost-effectiveness. Attendees will gain actionable strategies to minimize time-to-market and maximize return on investment, ensuring successful commercial launches. Join us to learn how to effectively manage the complexities and sensitivities of advancing from pre-clinical trials to commercial deployment.

Content provided by our supplier

Aragen Life Sciences

  • IN
  • 2019
    On CPHI since
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Research Organisation (CRO)
Primary activities
Agrochemical
API Producer
Biopharmaceutical
Chemical Development
Clinical Research
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Generic APIs producer
Intermediates Manufacturer
Nutraceuticals

Other Content from Aragen Life Sciences (2)